{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:14:39Z","timestamp":1784754879185,"version":"3.55.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13421-0","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:58:14Z","timestamp":1736337494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas"],"prefix":"10.1186","volume":"25","author":[{"given":"Julia","family":"Pikul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin M.","family":"Machnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rzepakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Winiarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Chudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Moskowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Kr\u00f3l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Fus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Kostrzewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Stok\u0142osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"3","key":"13421_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"13421_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102959","volume":"152","author":"G Gatta","year":"2020","unstructured":"Gatta G, et al. Major and minor salivary gland tumours. Crit Rev Oncol Hematol. 2020;152: 102959.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"13421_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/00016480500401035","volume":"126","author":"I Schwentner","year":"2006","unstructured":"Schwentner I, et al. Distant metastasis of parotid gland tumors. Acta Otolaryngol. 2006;126(4):340\u20135.","journal-title":"Acta Otolaryngol"},{"issue":"13","key":"13421_CR4","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1245\/s10434-016-5356-3","volume":"23","author":"SJ Nam","year":"2016","unstructured":"Nam SJ, et al. Risk Factors and Survival Associated with Distant Metastasis in Patients with Carcinoma of the Salivary Gland. Ann Surg Oncol. 2016;23(13):4376\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"13421_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.coms.2018.08.007","volume":"31","author":"ER Carlson","year":"2019","unstructured":"Carlson ER, Schlieve T. Salivary Gland Malignancies. Oral Maxillofac Surg Clin North Am. 2019;31(1):125\u201344.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"13421_CR6","unstructured":"Young A, Okuyemi OT. Malignant Salivary Gland Tumors, in StatPearls. 2022, StatPearls Publishing Copyright \u00a9. Treasure Island (FL): StatPearls Publishing LLC. 2022."},{"key":"13421_CR7","volume-title":"Head and Neck tumours. WHO classifcation of tumours series","author":"WHO Classiffcation of Tumours Editorial Board","year":"2022","unstructured":"WHO Classiffcation of Tumours Editorial Board. Head and Neck tumours. WHO classifcation of tumours series. 5th ed. Lyon: IARC; 2022.","edition":"5"},{"issue":"Suppl 2","key":"13421_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1054\/bjoc.2001.1762","volume":"84 Suppl 2","author":"RJ Bensadoun","year":"2001","unstructured":"Bensadoun RJ, et al. Malignant tumours of the salivary glands. Br J Cancer. 2001;84 Suppl 2(Suppl 2):42\u20138.","journal-title":"Br J Cancer."},{"issue":"17","key":"13421_CR9","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger JL, et al. Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol. 2021;39(17):1909\u201341.","journal-title":"J Clin Oncol"},{"issue":"6","key":"13421_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C van Herpen","year":"2022","unstructured":"van Herpen C, et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2022;7(6): 100602.","journal-title":"ESMO Open"},{"key":"13421_CR11","doi-asserted-by":"crossref","unstructured":"Vathiotis IA, Johnson JM, Argiris A. New Systemic Therapies in Salivary Gland Cancer. In: Critical Issues in Head and Neck Oncology. Cham: Springer International Publishing.\u00a02023.","DOI":"10.1007\/978-3-031-23175-9_20"},{"issue":"3","key":"13421_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","volume":"35","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto R, et al. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017;35(3):352\u201360.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13421_CR13","first-page":"4092","volume":"11","author":"S Sahara","year":"2021","unstructured":"Sahara S, Herzog AE, N\u00f6r JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021;11(9):4092\u2013110.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"13421_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3322\/caac.21600","volume":"70","author":"JJH Park","year":"2020","unstructured":"Park JJH, et al. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125\u201337.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"13421_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","volume":"11","author":"C Philpott","year":"2017","unstructured":"Philpott C, et al. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017;11(1):13.","journal-title":"Hum Genomics"},{"issue":"15","key":"13421_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"14","key":"13421_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"7993","key":"13421_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen S, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993):92\u2013100.","journal-title":"Nature"},{"issue":"4","key":"13421_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. 2016;99(4):877\u201385.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"13421_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41588-018-0167-z","volume":"50","author":"L Sundaram","year":"2018","unstructured":"Sundaram L, et al. Predicting the clinical impact of human mutation with deep neural networks. Nat Genet. 2018;50(8):1161\u201370.","journal-title":"Nat Genet"},{"issue":"3","key":"13421_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176(3):535-548.e24.","journal-title":"Cell"},{"issue":"1","key":"13421_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13073-020-00803-9","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu X, et al. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12(1):103.","journal-title":"Genome Med"},{"issue":"Database issue","key":"13421_CR23","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-5.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"13421_CR24","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47(D1):D941-d947.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"13421_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"13421_CR26","doi-asserted-by":"publisher","unstructured":"Stawi\u0144ski P, P\u0142oski R. Genebe.net: Implementation and validation of an automatic ACMG variant pathogenicity criteria assignment. Clin Genet. 2024;106(2):119\u201326.\u00a0https:\/\/doi.org\/10.1111\/cge.14516.","DOI":"10.1111\/cge.14516"},{"issue":"11","key":"13421_CR27","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos C, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978\u201380.","journal-title":"Bioinformatics"},{"issue":"4","key":"13421_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016;12(4): e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"13421_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"1","key":"13421_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz SP, et al. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discov. 2024;14(1):49\u201365.","journal-title":"Cancer Discov"},{"key":"13421_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;1:1\u201316.","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"13421_CR32","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho AS, et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129(10):4276\u201389.","journal-title":"J Clin Invest"},{"issue":"2","key":"13421_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","volume":"38","author":"C Even","year":"2020","unstructured":"Even C, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs. 2020;38(2):402\u20139.","journal-title":"Invest New Drugs"},{"issue":"6349","key":"13421_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"5","key":"13421_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ijc.33811","volume":"150","author":"A Neiheisel","year":"2022","unstructured":"Neiheisel A, et al. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer. 2022;150(5):727\u201340.","journal-title":"Int J Cancer"},{"key":"13421_CR36","doi-asserted-by":"publisher","unstructured":"Kommalapati A, et al. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel). 2021;13(12):2968. https:\/\/doi.org\/10.3390\/cancers13122968.","DOI":"10.3390\/cancers13122968"},{"issue":"3","key":"13421_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/annonc\/mdw669","volume":"28","author":"ST Kim","year":"2017","unstructured":"Kim ST, et al. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1\/2 inhibition. Ann Oncol. 2017;28(3):547\u201354.","journal-title":"Ann Oncol"},{"issue":"36","key":"13421_CR38","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","volume":"39","author":"AN Guterres","year":"2020","unstructured":"Guterres AN, Villanueva J. Targeting telomerase for cancer therapy. Oncogene. 2020;39(36):5811\u201324.","journal-title":"Oncogene"},{"key":"13421_CR39","unstructured":"Global Cancer Observatory. International Agency for Research on Cancer. Cancer Tomorrow. Available from: https:\/\/gco.iarc.fr\/tomorrow\/en."},{"key":"13421_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101906","volume":"80","author":"G Lassche","year":"2019","unstructured":"Lassche G, et al. Advances and challenges in precision medicine in salivary gland cancer. Cancer Treat Rev. 2019;80: 101906.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"13421_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1): a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"8","key":"13421_CR42","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016;15(8):1781\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"13421_CR43","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"13421_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5114\/wo.2024.144288","volume":"28","author":"J Pikul","year":"2024","unstructured":"Pikul J, Rzepakowska A. Molecular landscape of salivary gland malignancies. What is already known? Contemporary Oncology\/Wsp\u00f3\u0142czesna Onkologia. 2024;28(3):201\u201316.","journal-title":"Contemporary Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"issue":"10","key":"13421_CR45","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","volume":"28","author":"JS Ross","year":"2017","unstructured":"Ross JS, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28(10):2539\u201346.","journal-title":"Ann Oncol"},{"issue":"7","key":"13421_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jgg.2020.07.001","volume":"47","author":"S Wang","year":"2020","unstructured":"Wang S, et al. Whole-exome sequencing reveals genetic underpinnings of salivary adenoid cystic carcinoma in the Chinese population. J Genet Genomics. 2020;47(7):397\u2013401.","journal-title":"J Genet Genomics"},{"issue":"7","key":"13421_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ng.2643","volume":"45","author":"AS Ho","year":"2013","unstructured":"Ho AS, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45(7):791\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"13421_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"13421_CR49","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","volume":"13","author":"P LoRusso","year":"2023","unstructured":"LoRusso P, et al. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human. Dose-Escalation Study Cancer Discov. 2023;13(8):1802\u201313.","journal-title":"Dose-Escalation Study Cancer Discov"},{"issue":"13_Supplement","key":"13421_CR50","doi-asserted-by":"publisher","first-page":"LB006t","DOI":"10.1158\/1538-7445.AM2021-LB006","volume":"81","author":"M Dumble","year":"2021","unstructured":"Dumble M, et al. Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development. Cancer Res. 2021;81(13_Supplement):LB006t.","journal-title":"Cancer Res."},{"key":"13421_CR51","unstructured":"A Phase 1\/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE). 2020."},{"issue":"9\u201310","key":"13421_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1101\/gad.347872.120","volume":"35","author":"AM Klein","year":"2021","unstructured":"Klein AM, et al. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev. 2021;35(9\u201310):575\u2013601.","journal-title":"Genes Dev"},{"key":"13421_CR53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev-pathol-012414-040349","volume":"11","author":"O Karni-Schmidt","year":"2016","unstructured":"Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. Annu Rev Pathol. 2016;11:617\u201344.","journal-title":"Annu Rev Pathol"},{"issue":"15","key":"13421_CR54","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1101\/gad.1941710","volume":"24","author":"JJ Manfredi","year":"2010","unstructured":"Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24(15):1580\u20139.","journal-title":"Genes Dev"},{"issue":"3","key":"13421_CR55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/abbs\/gmt147","volume":"46","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai). 2014;46(3):180\u20139.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"2","key":"13421_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"13421_CR57","first-page":"1215","volume":"21","author":"G Sequeiros-Santiago","year":"2009","unstructured":"Sequeiros-Santiago G, et al. Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep. 2009;21(5):1215\u201322.","journal-title":"Oncol Rep"},{"issue":"2","key":"13421_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.oraloncology.2004.08.004","volume":"41","author":"M Kishi","year":"2005","unstructured":"Kishi M, et al. Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. Oral Oncol. 2005;41(2):161\u20139.","journal-title":"Oral Oncol"},{"issue":"46","key":"13421_CR59","doi-asserted-by":"publisher","first-page":"75261","DOI":"10.18632\/oncotarget.12127","volume":"7","author":"I Gr\u00fcnewald","year":"2016","unstructured":"Gr\u00fcnewald I, et al. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas. Oncotarget. 2016;7(46):75261\u201372.","journal-title":"Oncotarget"},{"issue":"1","key":"13421_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/gcc.20619","volume":"48","author":"F Persson","year":"2009","unstructured":"Persson F, et al. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer. 2009;48(1):69\u201382.","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"13421_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/gcc.22827","volume":"59","author":"L Amoroso","year":"2020","unstructured":"Amoroso L, et al. Genomic coamplification of CDK4\/MDM2\/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosomes Cancer. 2020;59(5):277\u201385.","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"13421_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/PAS.0000000000001125","volume":"42","author":"X He","year":"2018","unstructured":"He X, et al. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis. Am J Surg Pathol. 2018;42(9):1143\u201355.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"13421_CR63","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/0008-5472.CAN-12-2086","volume":"73","author":"K Zhang","year":"2013","unstructured":"Zhang K, et al. Amplification of FRS2 and activation of FGFR\/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 2013;73(4):1298\u2013307.","journal-title":"Cancer Res"},{"issue":"274","key":"13421_CR64","doi-asserted-by":"publisher","first-page":"ra32","DOI":"10.1126\/scisignal.2003741","volume":"6","author":"M Kurokawa","year":"2013","unstructured":"Kurokawa M, et al. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal. 2013;6(274):ra32.","journal-title":"Sci Signal."},{"issue":"1","key":"13421_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103\u201319.","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"13421_CR66","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263\u201384.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"13421_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4149\/neo_2013_031","volume":"60","author":"L Sabova","year":"2013","unstructured":"Sabova L, Kretova M, Luciakova K. New insights into the role of NF1 in cancer. Neoplasma. 2013;60(3):233\u20139.","journal-title":"Neoplasma"},{"issue":"15","key":"13421_CR68","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"YS Yap","year":"2014","unstructured":"Yap YS, et al. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014;5(15):5873\u201392.","journal-title":"Oncotarget"},{"issue":"10","key":"13421_CR69","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/13543784.2023.2263836","volume":"32","author":"JS Giraud","year":"2023","unstructured":"Giraud JS, et al. NF1 alterations in cancers: therapeutic implications in precision medicine. Expert Opin Investig Drugs. 2023;32(10):941\u201357.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"13421_CR70","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/2159-8290.CD-13-0741","volume":"4","author":"EC de Bruin","year":"2014","unstructured":"de Bruin EC, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014;4(5):606\u201319.","journal-title":"Cancer Discov"},{"issue":"28","key":"13421_CR71","doi-asserted-by":"publisher","first-page":"25631","DOI":"10.18632\/oncotarget.4554","volume":"6","author":"S Kato","year":"2015","unstructured":"Kato S, et al. Genomic landscape of salivary gland tumors. Oncotarget. 2015;6(28):25631\u201345.","journal-title":"Oncotarget"},{"key":"13421_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.838911","volume":"12","author":"O Novoplansky","year":"2022","unstructured":"Novoplansky O, et al. Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12: 838911.","journal-title":"Front Oncol"},{"issue":"7","key":"13421_CR73","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0000000000001258","volume":"43","author":"M Urano","year":"2019","unstructured":"Urano M, et al. Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. Am J Surg Pathol. 2019;43(7):984\u201394.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"13421_CR74","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/PAS.0000000000001673","volume":"45","author":"M Nakaguro","year":"2021","unstructured":"Nakaguro M, et al. The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. Am J Surg Pathol. 2021;45(7):885\u201394.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"13421_CR75","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12105-019-01055-9","volume":"14","author":"NJ Rupp","year":"2020","unstructured":"Rupp NJ, et al. New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation. Head Neck Pathol. 2020;14(2):554\u20138.","journal-title":"Head Neck Pathol"},{"issue":"5","key":"13421_CR76","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/PPO.0000000000000616","volume":"28","author":"A Desilets","year":"2022","unstructured":"Desilets A, Ho AL. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise. Cancer J. 2022;28(5):363\u20138.","journal-title":"Cancer J"},{"issue":"9","key":"13421_CR77","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","volume":"19","author":"M Gilardi","year":"2020","unstructured":"Gilardi M, et al. Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Mol Cancer Ther. 2020;19(9):1784\u201396.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"13421_CR78","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020;126(17):3972\u201381.","journal-title":"Cancer"},{"key":"13421_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen J, et al. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100: 102287.","journal-title":"Cancer Treat Rev"},{"key":"13421_CR80","doi-asserted-by":"publisher","first-page":"1136248","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana B, et al. ARID1A in cancer: Friend or foe? Front Oncol. 2023;13:1136248.","journal-title":"Front Oncol"},{"issue":"6","key":"13421_CR81","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313.","journal-title":"Nat Med"},{"issue":"1","key":"13421_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal J, et al. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71.","journal-title":"J Biomed Sci"},{"issue":"7","key":"13421_CR83","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 2015;5(7):752\u201367.","journal-title":"Cancer Discov"},{"key":"13421_CR84","doi-asserted-by":"publisher","first-page":"1124147","DOI":"10.3389\/fonc.2023.1124147","volume":"13","author":"VA Yakovlev","year":"2023","unstructured":"Yakovlev VA, et al. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K\/Akt1-dependent mechanism of synthetic lethality. Front Oncol. 2023;13:1124147.","journal-title":"Front Oncol"},{"key":"13421_CR85","doi-asserted-by":"publisher","unstructured":"Bou Zerdan M, et al. Molecular Targets in Salivary Gland Cancers: A Comprehensive Genomic Analysis of 118 Mucoepidermoid Carcinoma Tumors. Biomedicines. 2023;11(2):519. https:\/\/doi.org\/10.3390\/biomedicines11020519.","DOI":"10.3390\/biomedicines11020519"},{"issue":"4","key":"13421_CR86","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/annonc\/mdw689","volume":"28","author":"K Wang","year":"2017","unstructured":"Wang K, et al. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol. 2017;28(4):748\u201353.","journal-title":"Ann Oncol"},{"issue":"1","key":"13421_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/gcc.20719","volume":"49","author":"SL Anzick","year":"2010","unstructured":"Anzick SL, et al. Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer. 2010;49(1):59\u201369.","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"13421_CR88","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","volume":"33","author":"SA Mueller","year":"2020","unstructured":"Mueller SA, et al. Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol. 2020;33(10):1896\u2013909.","journal-title":"Mod Pathol"},{"issue":"20","key":"13421_CR89","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/cncr.30179","volume":"122","author":"SI Chiosea","year":"2016","unstructured":"Chiosea SI, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016;122(20):3136\u201344.","journal-title":"Cancer"},{"issue":"7","key":"13421_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100150","volume":"36","author":"S Dogan","year":"2023","unstructured":"Dogan S, et al. Loss of CDKN2A\/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. Mod Pathol. 2023;36(7): 100150.","journal-title":"Mod Pathol"},{"issue":"7","key":"13421_CR91","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/1066896917709350","volume":"25","author":"NA Cipriani","year":"2017","unstructured":"Cipriani NA, et al. Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A\/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017;25(7):613\u20138.","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"13421_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2022.07.016","volume":"143","author":"IZM Kreuger","year":"2023","unstructured":"Kreuger IZM, et al. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. J Invest Dermatol. 2023;143(1):18-25.e1.","journal-title":"J Invest Dermatol"},{"key":"13421_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, et al. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"issue":"1","key":"13421_CR94","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41467-022-29081-2","volume":"13","author":"J Ni","year":"2022","unstructured":"Ni J, et al. p16(INK4A)-deficiency predicts response to combined HER2 and CDK4\/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022;13(1):1473.","journal-title":"Nat Commun"},{"issue":"2","key":"13421_CR95","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.gendis.2023.02.050","volume":"11","author":"A Gajos-Michniewicz","year":"2024","unstructured":"Gajos-Michniewicz A, Czyz M. WNT\/\u03b2-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. Genes Dis. 2024;11(2):727\u201346.","journal-title":"Genes Dis"},{"key":"13421_CR96","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.critrevonc.2015.12.005","volume":"99","author":"Y Duchartre","year":"2016","unstructured":"Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"13421_CR97","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13000-018-0726-8","volume":"13","author":"Y Oyama","year":"2018","unstructured":"Oyama Y, et al. Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study. Diagn Pathol. 2018;13(1):48.","journal-title":"Diagn Pathol"},{"issue":"4","key":"13421_CR98","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.prp.2017.12.016","volume":"214","author":"M Sato","year":"2018","unstructured":"Sato M, et al. Wnt\/\u03b2-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. Pathol Res Pract. 2018;214(4):586\u201392.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"13421_CR99","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12105-015-0657-6","volume":"10","author":"BA Tesdahl","year":"2016","unstructured":"Tesdahl BA, et al. Epithelial-Mesenchymal Transition Protein Expression in Basal Cell Adenomas and Basal Cell Adenocarcinomas. Head Neck Pathol. 2016;10(2):176\u201381.","journal-title":"Head Neck Pathol"},{"issue":"D1","key":"13421_CR100","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52(D1):D1210-d1217.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"13421_CR101","doi-asserted-by":"publisher","first-page":"18224","DOI":"10.18632\/oncotarget.4015","volume":"6","author":"I Gr\u00fcnewald","year":"2015","unstructured":"Gr\u00fcnewald I, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget. 2015;6(20):18224\u201337.","journal-title":"Oncotarget"},{"issue":"12","key":"13421_CR102","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/modpathol.3800209","volume":"17","author":"T Daa","year":"2004","unstructured":"Daa T, et al. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol. 2004;17(12):1475\u201382.","journal-title":"Mod Pathol"},{"key":"13421_CR103","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12967-014-0299-6","volume":"12","author":"BM Ku","year":"2014","unstructured":"Ku BM, et al. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 2014;12:299.","journal-title":"J Transl Med"},{"issue":"2","key":"13421_CR104","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1159\/000515783","volume":"14","author":"H Bravo Thompson","year":"2021","unstructured":"Bravo Thompson H, et al. Parotid Myoepithelial Carcinoma in a Pediatric Patient with Multiple Recurrences: Case Report. Case Rep Oncol. 2021;14(2):989\u201397.","journal-title":"Case Rep Oncol"},{"issue":"24","key":"13421_CR105","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1111\/bph.13894","volume":"174","author":"MH Kagey","year":"2017","unstructured":"Kagey MH, He X. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol. 2017;174(24):4637\u201350.","journal-title":"Br J Pharmacol"},{"key":"13421_CR106","doi-asserted-by":"publisher","unstructured":"Liu T, Yuan X, Xu D. Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes (Basel). 2016;7(7):38. https:\/\/doi.org\/10.3390\/genes7070038.","DOI":"10.3390\/genes7070038"},{"issue":"34","key":"13421_CR107","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","volume":"38","author":"X Yuan","year":"2019","unstructured":"Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172\u201383.","journal-title":"Oncogene"},{"issue":"1","key":"13421_CR108","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12105-021-01346-0","volume":"16","author":"C Cormier","year":"2022","unstructured":"Cormier C, Agarwal S. Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression. Head Neck Pathol. 2022;16(1):322\u201330.","journal-title":"Head Neck Pathol"},{"issue":"1","key":"13421_CR109","doi-asserted-by":"publisher","first-page":"64","DOI":"10.30699\/ijp.2023.556651.2927","volume":"18","author":"A Zare-Mirzaie","year":"2023","unstructured":"Zare-Mirzaie A, et al. TERT Promoter Mutation in Benign and Malignant Salivary Gland Tumors. A Cross-Sectional Study Iran J Pathol. 2023;18(1):64\u201374.","journal-title":"A Cross-Sectional Study Iran J Pathol"},{"issue":"2","key":"13421_CR110","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116\u201329.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"13421_CR111","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2741\/4609","volume":"23","author":"T Ishiwata","year":"2018","unstructured":"Ishiwata T. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front Biosci (Landmark Ed). 2018;23(4):626\u201339.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"13421_CR112","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855\u201362.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"13421_CR113","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215\u201366.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"6","key":"13421_CR114","doi-asserted-by":"publisher","first-page":"101042831770742","DOI":"10.1177\/1010428317707424","volume":"39","author":"G Liu","year":"2017","unstructured":"Liu G, et al. Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis. Tumour Biol. 2017;39(6):1010428317707424.","journal-title":"Tumour Biol"},{"issue":"3","key":"13421_CR115","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155220983425","volume":"27","author":"A Weaver","year":"2021","unstructured":"Weaver A, Bossaer JB. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. J Oncol Pharm Pract. 2021;27(3):702\u201310.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"13421_CR116","first-page":"211","volume":"27","author":"J Pikul","year":"2023","unstructured":"Pikul J, et al. FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma. Contemp Oncol (Pozn). 2023;27(3):211\u20136.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"13421_CR117","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-017-01178-z","volume":"8","author":"MG Dalin","year":"2017","unstructured":"Dalin MG, et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun. 2017;8(1):1197.","journal-title":"Nat Commun"},{"issue":"18","key":"13421_CR118","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","volume":"22","author":"MG Dalin","year":"2016","unstructured":"Dalin MG, et al. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clin Cancer Res. 2016;22(18):4623\u201333.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13421-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T13:04:02Z","timestamp":1736341442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13421-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13421"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13421-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}